Federal Track

To view PPTicon-web  PowerPoint presentations click here.

To learn more about individual breakout sessions click on the title name (Updated 3-25-16):

Tuesday
Rx Drug Use and Misuse: Prevention and Treatment Programs at the State/Community Level
The Emerging Illicit Fentanyl Overdose Epidemic: Perspectives from the National and State Levels
Curbing Prescription Drug Abuse with Patient Review and Restriction Programs
 
Wednesday
National HIDTA Program
[Vision Session] The Importance of Collaboration Between State Leaders and the Medical Community to Reduce Opioid Abuse
DEA 360 Strategy: Working Together to Break the Cycle of Drug Trafficking, Drug Violence and Drug Abuse

Overview
Whether on the front lines in the fight against Rx drug and other opiate abuse, or serving as an elected or appointed official seeking solutions, stakeholders nationwide are unified in their desire to raising public awareness of the impacts of this dangerous epidemic. Working to identify trends, examine possible solutions, provide early intervention to individuals at risk of abuse, and caring for those already addicted can be a daunting task when acting alone. The Federal Track will examine a number of initiatives at the community, state and national levels designed to enhance collaboration among advocates, healthcare and law enforcement professionals. Attendees will hear from leaders of national organizations, medical directors, state attorneys general, and top federal officials who are tasked with developing and implementing innovative strategies, as well as enforcing policies and laws.
Rx Drug Use and Misuse: Prevention and Treatment Programs at the State/Community Level
Tuesday, March 29, 2016, 11:15 am – 12:30 pm
CE certified None
Presenters Travis Fretwell, MAC, NCAC II, CCS
Director, Georgia Department of Behavioral Health and Developmental Disabilities
 
Kevin Gabbert, LISW, IAADC
Access to Recovery Project Director, Iowa Department of Public Health
 
Monica Wilke-Brown, LMSW
Director, Screening, Brief Intervention and Referral to Treatment Project, Iowa Department of Public Health
Moderator Mitra Ahadpour, MD, DABAM
Medical Officer, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration
Session Description The session will showcase examples of success stories of prevention and treatment programs at the state and/or community level, specifically highlighting two Substance Abuse and Mental Health Services Administration (SAMHSA) grant programs: 1) Strategic Prevention Framework Partnerships for Success (SPF-PFS) State and Tribal Initiative, and 2) Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction (MAT-PDOA). Presenters will highlight progress made toward preventing Rx drug use and misuse among 12- to 25-year-olds, as well as provide strategies for expanding treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based MAT and recovery support services to individuals with opioid-use disorders seeking or receiving MAT.
Learning Objectives 1. Identify at least three strategies to prevent prescription drug misuse, abuse, and diversion.
2. Understand the importance of collaboration between various governmental entities and non-traditional partners to prevent prescription drug abuse and misuse.
3. Learn methods for expanding treatment service systems to include MAT in addressing opioid use disorders.
4. Learn about opportunities to leverage existing funding sources to meet client treatment/recovery.
Return to the top
The Emerging Illicit Fentanyl Overdose Epidemic: Perspectives from the National and State Levels
Tuesday, March 29, 2016, 4:15 pm – 5:30 pm
CE certified None
Presenters R. Matthew Gladden, PhD
Behavioral Scientist, PDO Surveillance and Epidemiology Team, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention
 
John Halpin, MD, MPH
Medical Officer, PDO Surveillance and Epidemiology Team, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention
Moderator Regina M. LaBelle, JD
Chief of Staff, White House Office of National Drug Control Policy, and Member, Rx & Heroin Summit National Advisory Board
Session Description This session will explore the emerging issue of overdoses involving illicitly manufactured fentanyl, a powerful synthetic opioid, often packaged and sold as heroin. In a general epidemiologic overview of the rising fentanyl problem in the United States, a Centers for Disease Control and Prevention (CDC) expert will explain what is known about the increase in fentanyl overdoses on a national scale, compare trends in national fentanyl confiscation data to trends in national fentanyl mortality data, and review measures that have been recommended by CDC for response to the epidemic. A CDC expert will discuss the results and recommendations resulting from an epidemiologic investigation (EpiAid) in response to the sharp increase in fentanyl overdoses in Ohio. A state epidemiologist will highlight one state’s experience with the rising issue of fentanyl-related mortality, and the measures the state has taken in response to the epidemic.
Learning Objectives 1. Explain the epidemiology of the rise in fentanyl overdoses in the United States.
2. Identify lessons learned during an epidemiologic investigation of a sharp increase in fentanyl overdoses in Ohio.
3. Describe one state’s experience with and responses to the fentanyl overdose epidemic.
Return to the top
Curbing Prescription Drug Abuse with Patient Review and Restriction Programs
Tuesday, March 29, 2016, 5:45 pm – 7:00 pm
CE certified None
Panelists Grant T. Baldwin, PhD, MPH
Director, Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, and Member, Rx and Heroin Summit National Advisory Board
 
Cecelia M. “CeCe” Spitznas, PhD
Senior Science Policy Advisor, White House Office of National Drug Control Policy
 
Jennifer Welch, MPH
Officer, The Pew Charitable Trusts
Moderator Regina M. LaBelle, JD
Chief of Staff, White House Office of National Drug Control Policy, and Member, Rx & Heroin Summit National Advisory Board
Session Description The Pew Charitable Trusts, the Centers for Disease Control and Prevention (CDC) and the Office of National Drug Control Policy (ONDCP) will host this panel discussion on the use of patient review and restriction programs (PRRs) as tools to help curb Rx drug abuse and coordinate patient care. These programs require patients at risk of drug abuse to use a designated prescriber and pharmacy to obtain controlled substance prescriptions. PRRs allow plan sponsors to better coordinate patient care and prevent inappropriate access to medications. The Pew representative will provide an overview of PRRs, share results from its survey of state Medicaid PRR programs and describe recent efforts in expanding these programs to Medicare. The CDC representative will speak to the inclusion of PRRs in its new Prescription Drug Overdose Prevention for States grant. The ONDCP representative will discuss how PRRs are included in its forthcoming national strategy and the inclusion of the policy in the President’s FY2016 Budget.
Learning Objectives 1. Explain the value of patient review and restriction programs (PRRs) as tools to help curb Rx drug abuse and coordinate patient care.
2. Describe state Medicaid PRR programs and recent efforts to expand PPR programs to Medicare.
3. Describe the role of PRR programs in the CDC’s Prescription Drug Overdose Prevention for States grant, ONDCP national strategy and federal budget.
Return to the top
National HIDTA Program
Wednesday, March 30, 2016, 12:30 pm – 1:45 pm
CE certified None
Presenters James F. Bohn
Director, Wisconsin High Intensity Drug Trafficking Area
 
Shannon Kelly, MA
Deputy Director, National HIDTA Program, Office of National Drug Control Policy
 
Jack Killorin
Director, Atlanta-Carolinas High Intensity Drug Trafficking Area
Moderator Sarah T. Melton, PharmD
Associate Professor of Pharmacy Practice, Gatton College of Pharmacy, East Tennessee State University
Session Description This presentation will provide an overview of the High Intensity Drug Trafficking Areas (HIDTA) program, highlighting potential areas of collaboration in various regions and discussing examples of a few specific HIDTAs and their innovative initiatives. The HIDTA program provides assistance to federal, state, local and tribal law enforcement agencies working in regions where drug-trafficking is particularly prevalent. The program facilitates cooperation and information sharing among law enforcement agencies, provides law enforcement intelligence, prepares annual threat assessments, and acts as a force multiplier of regional efforts. There are currently 28 HIDTAs nationwide, with HIDTA-designated counties located in 48 states. Each HIDTA implements initiatives tailored to reduce the unique drug threats in each HIDTA’s area. Treatment and prevention related initiatives, as well as other public health-focused efforts, have also become critical components of the HIDTA program. Examples of specific HIDTA operations and initiatives will be discussed in detail.
Learning Objectives 1. Explain the HIDTA program.
2. Identify potential areas for collaboration in drug-trafficking responses in various regions of the country.
3. Describe innovative HIDTA operations and initiatives.
Return to the top
Vision Session: The Importance of Collaboration Between State Leaders and the Medical Community to Reduce Opioid Abuse
Wednesday, March 30, 2016, 2:00 pm – 3:15 pm
CE certified None
  Presented by:
National Association of Attorneys General
Presenters Honorable Samuel “Sam” Olens, JD
Attorney General, State of Georgia
 
Yngvild Olsen, MD, MPH
Medical Director, Institutes for Behavior Resources, Inc.
 
Honorable Brad Schimel, JD
Attorney General, State of Wisconsin
Session Description While the jurisdiction of state attorneys general varies, all attorneys general have been on the frontline of combating opioid trafficking and addiction in their states and territories through increasing public awareness, decreasing stigma, and working with stakeholders to tackle this epidemic. Some of the most important stakeholders in this crisis are those in the medical community. This panel, which includes two attorneys general who have made addressing opioid addiction a priority in their states, and the Director-at-Large of the American Society of Addiction Medicine, will highlight the importance of collaboration between the medical and legal communities and describe some innovative policies and strategies, prescriber education initiatives, the expansion of prescription drug monitoring programs, and the need to reduce the stigma associated with addiction.
Return to the top
DEA 360 Strategy: Working Together to Break the Cycle of Drug Trafficking, Drug Violence and Drug Abuse
Wednesday, March 30, 2016, 3:30 pm – 4:45 pm
CE certified None
Presenters Neil D. Doherty
Associate Deputy Assistant Administrator, Office of Diversion Control, United States Drug Enforcement Administration
 
Harry J. Giknavorian, JD
Executive Assistant, Office of Diversion Control, United States Drug Enforcement Administration
Moderator Nancy Hale, MA
President and CEO, Operation UNITE
Session Description This session will provide an overview of the Drug Enforcement Administration (DEA) 360 Strategy. This strategy is a comprehensive approach tackling the cycle of violence and addiction generated by the link between drug cartels, violent gangs and the rising problem of Rx opioid and heroin abuse in U.S. cities. DEA 360 involves: coordinated law enforcement operations targeting all levels of drug trafficking organizations and violent gangs supplying drugs to our neighborhoods; engaging drug manufacturers, wholesalers, practitioners and pharmacists through diversion control to increase awareness of the opioid epidemic and encourage responsible prescribing practices, and use of opioid painkillers throughout the medical community; and community outreach and partnership with local organizations following enforcement operations, equipping and empowering communities to fight the opioid epidemic.
Learning Objectives 1. Explain the DEA 360 Strategy.
2. Describe partnering efforts with the medical community and others to raise awareness of the dangers of Rx opioid misuse and the link to heroin.
3. Describe efforts to strengthen community organizations best positioned to provide long-term help and support for building drug-free communities.
Return to the top
The content and scheduled time of these breakout sessions are subject to change.